GLP-1 Weight Loss Telehealth

GLP-1 receptor agonists have changed obesity medicine. They are also the basis of one of the largest direct-to-consumer telehealth markets in years. The model varies enormously: some clinics are doing thoughtful obesity medicine with a long-term plan; some are running scripts with minimal screening. This page explains what to look for, what the FDA-approved vs. compounded distinction actually means, and which questions a real clinician should be asking you.

The short version

Semaglutide and tirzepatide are different molecules from different manufacturers, both available in FDA-approved injectable forms for diabetes and for weight management at specific doses.
Compounded versions of GLP-1s emerged during FDA-recognized drug shortages. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, and the grace periods for compounding "essentially copies" ended in spring 2025.
Oral options now exist: the Wegovy pill (oral semaglutide, approved December 2025) and orforglipron (Foundayo, approved April 2026).
A reasonable evaluation includes weight history, cardiometabolic screening, and review of contraindications (personal or family history of medullary thyroid carcinoma or MEN2; history of pancreatitis).
Side effects are common: nausea, vomiting, constipation or diarrhea, fatigue. Severe side effects are less common but real.
These medications work while you take them; weight regain is common after stopping. The long-term plan matters.
Insurance coverage of GLP-1s for weight loss is inconsistent; many patients pay out of pocket.

The medications

Two injectable molecules dominate the current weight-loss conversation: semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP and GLP-1 receptor agonist). Each is sold by its manufacturer under specific brand names for diabetes (semaglutide as Ozempic; tirzepatide as Mounjaro) and for chronic weight management at specific doses (semaglutide as Wegovy; tirzepatide as Zepbound). Liraglutide is an earlier GLP-1 with similar mechanism, less weight-loss efficacy in head-to-head comparisons, and a daily rather than weekly dosing schedule. Newer oral options include the Wegovy pill (oral semaglutide 25 mg, FDA-approved December 2025) and orforglipron (Foundayo, a non-peptide oral GLP-1 approved April 2026).

The FDA-approved indications and dosing differ by product. The diabetes products and weight management products are not technically interchangeable in label terms, although the underlying molecule is the same in some cases. Off-label use of diabetes-labeled products for weight loss has been common.

FDA-approved vs. compounded

During FDA-recognized drug shortages, compounding pharmacies in the US can legally produce versions of medications that are otherwise FDA-approved. Many of the lower-priced telehealth weight-loss services launched on this basis, supplying compounded semaglutide and tirzepatide while the brand-name products were in shortage. The FDA has periodically updated the shortage status of these molecules; as shortages have resolved or partially resolved, the legal basis for continued large-scale compounding of equivalent versions has tightened. The FDA has also raised concerns about salt forms of these molecules (semaglutide sodium, semaglutide acetate) that are not the active ingredient in the FDA-approved products.

Specifically, the FDA removed tirzepatide from its shortage list (final decision December 19, 2024) and semaglutide (February 21, 2025), and its enforcement grace periods for compounding copies of these drugs ended between February and May 2025. Some compounded GLP-1 telehealth services have continued operating by offering "personalized" doses or added ingredients, an approach the FDA has scrutinized; others switched to brand-name products. The current state of the rules is worth verifying directly with FDA guidance, because what was legal six months ago may not be legal now. A service that is opaque about whether it is supplying FDA-approved or compounded product is not being straight with you.

Required screening

A reasonable initial evaluation should include:

Height, weight, BMI, and waist circumference where available.
Weight history and prior weight-loss attempts.
Cardiovascular history and current blood pressure. See measuring your own vitals at home.
Diabetes status, with HbA1c if not recent.
Lipid panel.
Personal or family history of medullary thyroid carcinoma or MEN2 (a contraindication for GLP-1 receptor agonists per FDA labeling).
History of pancreatitis or gallbladder disease.
Pregnancy plans and contraception (these medications are not used in pregnancy).
Medication list and allergies.
Mental health history, including any history of eating disorders.

A service that does not ask about most of this is not doing the work of a clinician.

Side effects and what to watch for

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal pain, and reflux. They are usually most prominent during dose escalation and tend to improve over weeks. Reduced appetite is the intended effect; profound food aversion or significant lean mass loss is not.

Less common but more serious effects include pancreatitis, gallbladder disease (cholelithiasis and cholecystitis), kidney injury (often related to dehydration from severe vomiting), and gastroparesis. There are theoretical concerns about thyroid C-cell tumors based on rodent data; humans with personal or family history of medullary thyroid carcinoma or MEN2 should not use these drugs. Reports of suicidality have prompted ongoing investigation; the FDA has reviewed available data and updated labeling guidance.

A clinician who manages side effects — adjusting dose, slowing titration, addressing dehydration, evaluating concerning symptoms — is doing the work. A service that simply refills the next month's dose regardless of how you are doing is not.

The long-term question

GLP-1 receptor agonists work while patients take them. Trial data and clinical experience consistently show substantial weight regain after stopping. This raises a real question: if these medications work, are they meant to be lifelong therapy? For many patients, the answer is probably yes — analogous to other chronic medical conditions where ongoing pharmacotherapy is the standard. But the cost, the supply situation, and the patient's own life circumstances make this a non-trivial conversation.

A reasonable service raises this question explicitly rather than leaving the patient to discover it. A care plan should include: lifestyle and behavioral support that builds skills durable beyond the medication, monitoring of muscle mass and nutritional status, a discussion of what happens if access ends, and consideration of dose tapering or maintenance strategies. None of this is unique to telehealth; what is unique is that some telehealth services have framed GLP-1s as a quick fix without engaging with the long-term question.

Insurance, cost, and access

List prices for brand-name GLP-1s for weight loss have been around a thousand dollars per month or more. Since 2025, manufacturers have also sold some products directly to self-pay patients at substantially lower cash prices (for example through LillyDirect, NovoCare, and the federal TrumpRx site); those prices change often, so check the manufacturer's current price rather than relying on a figure quoted by a telehealth service. Insurance coverage for weight-loss indications is inconsistent: some plans cover them with prior authorization and BMI thresholds; many do not. Coverage for diabetes is broader. Manufacturer savings programs reduce out-of-pocket costs for some patients. Compounded products were often substantially cheaper, which is much of why telehealth services using them grew quickly. With the shortages over, lower manufacturer cash prices and insurance coverage are now the main routes to affordable FDA-approved products.

What a thoughtful service does

Real evaluation by a licensed clinician, with screening as above.
Clear disclosure of whether the product is FDA-approved or compounded, and from where.
Discussion of expected effects, side effects, and the long-term plan.
A clinician who is reachable for side effect management, not just refills.
Behavioral and nutritional support, ideally including a registered dietitian.
Monitoring of weight, BP, side effects, and (when relevant) lab values over time.
Coordination with primary care.
Plan for dose adjustments, hold periods, or discontinuation if needed.

Red flags

Approval and shipment within hours of a brief questionnaire, with no clinician interaction.
No screening for thyroid history, pancreatitis history, or pregnancy plans.
Vague or shifting answers about whether the product is FDA-approved or compounded.
No clinician name visible; no licensed clinician you can verify.
Subscription model with auto-refill regardless of side effects or response.
No path to handle side effects or discontinue safely.
Marketing that minimizes side effects or risks.

See red flags in any remote care service.

What to ask

Will I be evaluated by a licensed clinician? What credentials do they have?
Is the product FDA-approved or compounded? If compounded, by which pharmacy?
What screening do you require? Will you require my labs?
What is the plan if I have side effects?
What is the long-term plan — for as long as I want to remain at my new weight?
How is your service different from buying pen refills as a "subscription"?
Will you communicate with my primary care?
What does it cost — including initial visit, monthly medication, and follow-ups?

When this is not enough

For some patients, integrated obesity medicine — a clinician working closely with a registered dietitian, a behavioral specialist, and possibly a bariatric surgery program — is more appropriate than a single-medication service. For severe gastrointestinal symptoms, suspected pancreatitis, suspected gallbladder disease, or other significant side effects, in-person evaluation is appropriate. See when telehealth is not enough and choosing a primary care telehealth service.

GLP-1 weight loss telehealth